## **Core Concept**
The question pertains to the management of Gestational Trophoblastic Disease (GTD), specifically focusing on the role of prophylactic chemotherapy. GTD encompasses a range of diseases including hydatidiform mole, invasive mole, choriocarcinoma, placental-site trophoblastic tumor, and epithelioid trophoblastic tumor. Prophylactic chemotherapy in GTD aims to prevent the progression to gestational trophoblastic neoplasia (GTN), particularly in high-risk cases.

## **Why the Correct Answer is Right**
Prophylactic chemotherapy in GTD is considered for patients with high-risk factors for developing GTN. The **FIGO** (International Federation of Gynecology and Obstetrics) scoring system helps in identifying high-risk patients. Chemotherapy agents like **methotrexate** and **actinomycin D** are commonly used. The correct answer, **D. High-risk GTD**, is right because prophylactic chemotherapy is specifically considered for patients with high-risk GTD to prevent the development of GTN.

## **Why Each Wrong Option is Incorrect**
- **Option A: Low-risk GTD** - Prophylactic chemotherapy is not typically recommended for low-risk GTD as the risk of progression to GTN is lower, and the treatment approach often involves evacuation of the uterus and monitoring.
- **Option B: Recurrent GTD** - While recurrent GTD poses a challenge, prophylactic chemotherapy is not the standard preventive approach; rather, treatment is usually based on the histological type and extent of disease.
- **Option C. All GTD cases** - Not all GTD cases require prophylactic chemotherapy; the approach is more tailored to high-risk cases based on FIGO scores and other clinical factors.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the decision to use prophylactic chemotherapy in GTD is based on the **FIGO scoring system**, which assesses factors like age, hCG level, largest uterine size for dates, interval months from index pregnancy, and site and number of metastases. High-risk disease (typically a FIGO score ≥ 7) warrants aggressive management, including prophylactic chemotherapy.

## **Correct Answer:** D. High-risk GTD